Benitec Biopharma (BNTC) News Today $10.30 -0.76 (-6.87%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest UpdateBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 62,300 shares, a growth of 65.7% from the December 15th total of 37,600 shares. Based on an average daily trading volume, of 55,200 shares, the short-interest ratio is presently 1.1 days.January 15 at 8:30 PM | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Stock Crosses Below Fifty Day Moving Average - Should You Sell?Benitec Biopharma (NASDAQ:BNTC) Stock Passes Below Fifty Day Moving Average - Here's What HappenedJanuary 9, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Rating of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have assigned a strong bDecember 30, 2024 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 27,502 SharesDecember 27, 2024 | insidertrades.comBenitec Biopharma Inc. (NASDAQ:BNTC) Director Buys $301,971.96 in StockBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 27,502 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $10.98 per share, with a total value of $301,971.96. Following the acquisition, the director now owns 7,981,725 shares in the company, valued at $87,639,340.50. This trade represents a 0.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 26, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for BNTC Q2 Earnings?Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for Benitec Biopharma in a research report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.27) per share for the quartDecember 19, 2024 | marketbeat.comHedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC)December 18, 2024 | finance.yahoo.comBenitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright started coverage on Benitec Biopharma in a report on Monday. They issued a "buy" rating and a $28.00 price target for the company.December 16, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on Benitec Biopharma in a research report on Monday. They set a "buy" rating and a $28.00 price objective for the company.December 16, 2024 | marketbeat.comShort Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 6.9%Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 35,400 shares, an increase of 6.9% from the November 15th total of 33,100 shares. Based on an average daily volume of 39,100 shares, the days-to-cover ratio is presently 0.9 days.December 15, 2024 | marketbeat.comBenitec Biopharma Shakes Up Management TeamDecember 14, 2024 | marketwatch.comBaird Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationDecember 13, 2024 | msn.comRobert W. Baird Initiates Coverage on Benitec Biopharma (NASDAQ:BNTC)Robert W. Baird began coverage on Benitec Biopharma in a research report on Friday. They issued an "outperform" rating and a $30.00 target price on the stock.December 13, 2024 | marketbeat.comInsider Buying: Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys 42,000 Shares of StockDecember 6, 2024 | insidertrades.comBenitec Biopharma Inc. (NASDAQ:BNTC) Given Consensus Rating of "Buy" by AnalystsShares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendatDecember 5, 2024 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Shares Bought by Suvretta Capital Management LLCSuvretta Capital Management LLC raised its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 422.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,829,053 shares of the bioteNovember 29, 2024 | marketbeat.comBenitec Biopharma to Participate in Upcoming Investor Conferences in DecemberNovember 26, 2024 | globenewswire.comBenitec Biopharma IncNovember 23, 2024 | money.usnews.comBenitec Biopharma Awards Bonuses to Key ExecutivesNovember 16, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Benitec Biopharma (BNTC)November 16, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Grows Position in Benitec Biopharma Inc. (NASDAQ:BNTC)Simplify Asset Management Inc. boosted its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 127.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,535 shares of the biotechnology company's stock after purchasing an additional 65November 15, 2024 | marketbeat.comBenitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational UpdateNovember 14, 2024 | globenewswire.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Recommendation of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on theNovember 10, 2024 | marketbeat.comBenitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceNovember 4, 2024 | globenewswire.comBenitec Biopharma files $125M mixed securities shelfNovember 1, 2024 | markets.businessinsider.comBenitec Biopharma (BNTC) Receives a Buy from Piper SandlerOctober 19, 2024 | markets.businessinsider.comBenitec Biopharma: OPMD Program Continues To Advance With CatalystsOctober 17, 2024 | seekingalpha.comBenitec Biopharma Inc. (NASDAQ:BNTC) to Post Q1 2025 Earnings of ($0.54) Per Share, Leerink Partnrs ForecastsBenitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Benitec Biopharma in a report released on Monday, October 14th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earningsOctober 17, 2024 | marketbeat.comOppenheimer Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationOctober 17, 2024 | msn.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from BrokeragesBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been given an average rating of "Buy" by the five research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the compOctober 16, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Now Covered by OppenheimerOppenheimer assumed coverage on shares of Benitec Biopharma in a research report on Wednesday. They issued an "outperform" rating and a $35.00 price target for the company.October 16, 2024 | marketbeat.comBuy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive OutlookOctober 15, 2024 | markets.businessinsider.comBenitec Biopharma Announces Updated Investor Webcast InformationOctober 14, 2024 | globenewswire.comBenitec Reports Positive Phase 1b/2a Results For BB-301 In Oculopharyngeal Muscular DystrophyOctober 13, 2024 | markets.businessinsider.comBenitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle SocietyOctober 12, 2024 | globenewswire.comBenitec Biopharma's BB-301: Potential In OPMD But Still Too Early StagesOctober 9, 2024 | seekingalpha.comBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50 Day Moving Average - What's Next?Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?October 9, 2024 | marketbeat.comBenitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD TreatmentOctober 3, 2024 | msn.comBenitec Biopharma (NASDAQ:BNTC) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comBenitec Biopharma (NASDAQ:BNTC) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNantahala Capital Management LLC Buys New Shares in Benitec Biopharma Inc. (NASDAQ:BNTC)Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 841,395 shares of the biotOctober 1, 2024 | marketbeat.comBuy Rating Affirmed for Benitec Biopharma on Strong Clinical Progress and Solid FinancialsSeptember 30, 2024 | markets.businessinsider.comSuvretta Capital Management's Strategic Acquisition in Benitec Biopharma IncSeptember 30, 2024 | finance.yahoo.comJMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC)JMP Securities reiterated a "market outperform" rating and issued a $16.00 target price on shares of Benitec Biopharma in a research note on Monday.September 30, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth PlansSeptember 28, 2024 | finance.yahoo.comBenitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateSeptember 26, 2024 | globenewswire.comBenitec Biopharma Inc. (NASDAQ:BNTC) Sees Significant Decline in Short InterestBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 62,000 shares, a decrease of 6.8% from the August 15th total of 66,500 shares. Based on an average trading volume of 29,200 shares, the days-to-cover ratio is currently 2.1 days.September 18, 2024 | marketbeat.comBenitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietySeptember 18, 2024 | globenewswire.comBenitec Biopharma CEO to Participate in OPMD Awareness Day WebinarSeptember 17, 2024 | finance.yahoo.comGuggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy RecommendationSeptember 12, 2024 | msn.com Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTC Media Mentions By Week BNTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTC News Sentiment▼0.950.64▲Average Medical News Sentiment BNTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTC Articles This Week▼21▲BNTC Articles Average Week Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZYME News ADPT News GYRE News PSTX News OCS News NUVB News AVXL News ABCL News CVAC News AVBP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTC) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.